20 results
Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation

Thumbnail

D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report

Thumbnail

D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months

Thumbnail

D2.350 - Exploring the Psychological Burden of Hereditary Angioedema Using the Pictorial Representation of Illness and Self Measure (PRISM): Updated Insights from a Prospective Real-Life Cohort

Thumbnail

D2.351 - Germline Variant in the GNAI2 Gene Associated with Severe Immune Dysregulation and Autoimmune Hemolytic Anemia in a Pediatric Patient

Thumbnail

D2.352 - Epidermodysplasia verruciformis as a sign for STK4 deficiency

Thumbnail

D2.353 - Same Disease, Different Clinical Phenotypes: A20 Haploinsufficiency

Thumbnail

D2.354 - Evaluation of Subjective Sleep Quality and Psychological Status in Adult Patients with Inborn Errors of Immunity

Thumbnail

D2.362 - Clinical and Immunological Characteristics of Non-Infectious Complications in Common Variable Immunodeficiency: A Single-Center Retrospective Evaluation in Adult Patients with CVID

Thumbnail

D2.363 - Immunologic Basis of Coexisting Slowly Progressive Insulin-Dependent Diabetes Mellitus (SPIDDM) and Generalized Myasthenia Gravis (MG)

Thumbnail

D2.349 - RAPIDe‑3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks

Thumbnail

D2.357 - Reductions in Hereditary Angioedema Attacks among Patients with C1 Esterase Inhibitor Deficiency who Switched from Another Long-Term Prophylaxis to Berotralstat

Thumbnail

D2.360 - Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat

Thumbnail

D2.361 - Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat